Announcement • Jun 30
Porton Pharma Solutions Ltd. to Report First Half, 2026 Results on Aug 22, 2026 Porton Pharma Solutions Ltd. announced that they will report first half, 2026 results on Aug 22, 2026 New Risk • Jun 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.7% average weekly change). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Jun 29
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CN¥17.50, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 16x in the Pharmaceuticals industry in China. Total loss to shareholders of 39% over the past three years. Valuation Update With 7 Day Price Move • May 20
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to CN¥15.77, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total loss to shareholders of 49% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥29.10 per share. New Risk • May 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.3% average weekly change). Large one-off items impacting financial results. Announcement • Apr 03
Porton Pharma Solutions Ltd., Annual General Meeting, Apr 27, 2026 Porton Pharma Solutions Ltd., Annual General Meeting, Apr 27, 2026, at 13:30 China Standard Time. Announcement • Mar 31
Porton Pharma Solutions Ltd. to Report Q1, 2026 Results on Apr 23, 2026 Porton Pharma Solutions Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026 Announcement • Dec 31
Porton Pharma Solutions Ltd. to Report Fiscal Year 2025 Results on Apr 04, 2026 Porton Pharma Solutions Ltd. announced that they will report fiscal year 2025 results on Apr 04, 2026 Announcement • Sep 30
Porton Pharma Solutions Ltd. to Report Q3, 2025 Results on Oct 25, 2025 Porton Pharma Solutions Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025 Announcement • Jul 02
Porton Pharma Solutions Ltd. to Report First Half, 2025 Results on Aug 23, 2025 Porton Pharma Solutions Ltd. announced that they will report first half, 2025 results on Aug 23, 2025 Announcement • Apr 08
Porton Pharma Solutions Ltd., Annual General Meeting, Apr 28, 2025 Porton Pharma Solutions Ltd., Annual General Meeting, Apr 28, 2025, at 14:30 China Standard Time. Location: Lecture Hall of the Company's R and D Center in New Drug Outsourcing Service Base, Chongqing China Announcement • Mar 31
Porton Pharma Solutions Ltd. to Report Q1, 2025 Results on Apr 25, 2025 Porton Pharma Solutions Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025 Announcement • Dec 31
Porton Pharma Solutions Ltd. to Report Fiscal Year 2024 Results on Mar 29, 2025 Porton Pharma Solutions Ltd. announced that they will report fiscal year 2024 results on Mar 29, 2025 Reported Earnings • Oct 25
Third quarter 2024 earnings released: CN¥0.068 loss per share (vs CN¥0.075 profit in 3Q 2023) Third quarter 2024 results: CN¥0.068 loss per share (down from CN¥0.075 profit in 3Q 2023). Revenue: CN¥773.2m (up 11% from 3Q 2023). Net loss: CN¥36.4m (down 188% from profit in 3Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 45% per year and the company’s share price has also fallen by 45% per year. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change). Announcement • Sep 30
Porton Pharma Solutions Ltd. to Report Q3, 2024 Results on Oct 25, 2024 Porton Pharma Solutions Ltd. announced that they will report Q3, 2024 results on Oct 25, 2024 Reported Earnings • Aug 28
Second quarter 2024 earnings released: CN¥0.14 loss per share (vs CN¥0.20 profit in 2Q 2023) Second quarter 2024 results: CN¥0.14 loss per share (down from CN¥0.20 profit in 2Q 2023). Revenue: CN¥674.4m (down 30% from 2Q 2023). Net loss: CN¥75.2m (down 171% from profit in 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings. New Risk • Aug 27
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 1.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 99% Paying a dividend despite having no free cash flows. Earnings are forecast to decline by an average of 1.3% per year for the foreseeable future. Minor Risk Profit margins are more than 30% lower than last year (7.3% net profit margin). Announcement • Jun 29
Porton Pharma Solutions Ltd. to Report First Half, 2024 Results on Aug 28, 2024 Porton Pharma Solutions Ltd. announced that they will report first half, 2024 results on Aug 28, 2024 Announcement • May 25
Porton Pharma Solutions Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024 Porton Pharma Solutions Ltd. announced final cash dividend/10 shares (tax included) of CNY 4.87000000 on A shares for the year 2023. Record date: 28 May 2024. Ex-date: 29 May 2024. Payment date: 29 May 2024. Announcement • Apr 29
Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024 Porton Pharma Solutions Ltd., Annual General Meeting, May 20, 2024, at 14:30 China Standard Time. Location: 1F, R and D Building, No. 7, Yuntu Road, Beibei District, Chongqing China Reported Earnings • Apr 28
First quarter 2024 earnings released: CN¥0.17 loss per share (vs CN¥0.56 profit in 1Q 2023) First quarter 2024 results: CN¥0.17 loss per share (down from CN¥0.56 profit in 1Q 2023). Revenue: CN¥677.7m (down 51% from 1Q 2023). Net loss: CN¥94.9m (down 131% from profit in 1Q 2023). Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Announcement • Mar 30
Porton Pharma Solutions Ltd. to Report Q1, 2024 Results on Apr 27, 2024 Porton Pharma Solutions Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024 Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥17.74, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 16x in the Pharmaceuticals industry in China. Total loss to shareholders of 56% over the past three years. Announcement • Dec 29
Porton Pharma Solutions Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024 Porton Pharma Solutions Ltd. announced that they will report fiscal year 2023 results on Mar 30, 2024 New Risk • Dec 27
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 6.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 6.5% per year for the foreseeable future. High level of non-cash earnings (21% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (18% net profit margin). New Risk • Nov 01
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 21% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (21% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.6% average weekly change). Profit margins are more than 30% lower than last year (18% net profit margin). Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.075 (vs CN¥0.67 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.075 (down from CN¥0.67 in 3Q 2022). Revenue: CN¥698.3m (down 46% from 3Q 2022). Net income: CN¥41.5m (down 89% from 3Q 2022). Profit margin: 5.9% (down from 28% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. New Risk • Oct 21
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 3.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.0% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.1% average weekly change). Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥29.62, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total loss to shareholders of 3.5% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥27.89 per share. Reported Earnings • Aug 19
Second quarter 2023 earnings released: EPS: CN¥0.20 (vs CN¥1.53 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.20 (down from CN¥1.53 in 2Q 2022). Revenue: CN¥960.9m (down 61% from 2Q 2022). Net income: CN¥106.3m (down 87% from 2Q 2022). Profit margin: 11% (down from 34% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Jul 01
Porton Pharma Solutions Ltd. to Report First Half, 2023 Results on Aug 19, 2023 Porton Pharma Solutions Ltd. announced that they will report first half, 2023 results on Aug 19, 2023 Upcoming Dividend • May 02
Upcoming dividend of CN¥1.11 per share at 3.2% yield Eligible shareholders must have bought the stock before 09 May 2023. Payment date: 09 May 2023. Payout ratio is a comfortable 31% and this is well supported by cash flows. Trailing yield: 3.2%. Within top quartile of Chinese dividend payers (2.0%). Higher than average of industry peers (1.4%). Reported Earnings • Mar 27
Full year 2022 earnings released: EPS: CN¥3.70 (vs CN¥0.97 in FY 2021) Full year 2022 results: EPS: CN¥3.70 (up from CN¥0.97 in FY 2021). Revenue: CN¥7.03b (up 127% from FY 2021). Net income: CN¥2.01b (up 283% from FY 2021). Profit margin: 28% (up from 17% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jan 16
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥48.93, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Total returns to shareholders of 189% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥82.62 per share. Board Change • Nov 16
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Non Independent Director Weiqiang Yang was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.67 (vs CN¥0.27 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.67 (up from CN¥0.27 in 3Q 2021). Revenue: CN¥1.30b (up 68% from 3Q 2021). Net income: CN¥365.4m (up 150% from 3Q 2021). Profit margin: 28% (up from 19% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 50% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥52.35, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total returns to shareholders of 275% over the past three years. Reported Earnings • Aug 21
Second quarter 2022 earnings released: EPS: CN¥1.53 (vs CN¥0.23 in 2Q 2021) Second quarter 2022 results: EPS: CN¥1.53 (up from CN¥0.23 in 2Q 2021). Revenue: CN¥2.47b (up 247% from 2Q 2021). Net income: CN¥830.4m (up CN¥704.0m from 2Q 2021). Profit margin: 34% (up from 18% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 41%, compared to a 23% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 69% per year whereas the company’s share price has increased by 64% per year. Valuation Update With 7 Day Price Move • Jun 09
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥77.00, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 870% over the past three years. Board Change • Jun 01
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Non Independent Director Weiqiang Yang was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • May 02
High number of new and inexperienced directors There are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 5 experienced directors. No highly experienced directors. Non-Employee Representative Supervisor Xingming Li is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Apr 30
First quarter 2022 earnings released: EPS: CN¥0.70 (vs CN¥0.16 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.70 (up from CN¥0.16 in 1Q 2021). Revenue: CN¥1.44b (up 166% from 1Q 2021). Net income: CN¥381.9m (up 334% from 1Q 2021). Profit margin: 27% (up from 16% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 94%, compared to a 24% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has increased by 103% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Mar 03
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: CN¥0.97 (up from CN¥0.61 in FY 2020). Revenue: CN¥3.11b (up 50% from FY 2020). Net income: CN¥523.9m (up 62% from FY 2020). Profit margin: 17% (up from 16% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 6.3%. Over the next year, revenue is forecast to grow 50%, compared to a 25% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has increased by 97% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment deteriorated over the past week After last week's 19% share price decline to CN¥62.69, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Total returns to shareholders of 608% over the past three years. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.20 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: CN¥774.0m (up 38% from 3Q 2020). Net income: CN¥146.1m (up 35% from 3Q 2020). Profit margin: 19% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has increased by 122% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 15
Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.16 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥713.0m (up 33% from 2Q 2020). Net income: CN¥126.5m (up 53% from 2Q 2020). Profit margin: 18% (up from 16% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has increased by 121% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Apr 28
First quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.09 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥542.9m (up 39% from 1Q 2020). Net income: CN¥88.1m (up 83% from 1Q 2020). Profit margin: 16% (up from 12% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Mar 16
Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.35 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥2.07b (up 34% from FY 2019). Net income: CN¥324.4m (up 75% from FY 2019). Profit margin: 16% (up from 12% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥38.16, the stock is trading at a trailing P/E ratio of 63.6x, down from the previous P/E ratio of 76.3x. This compares to an average P/E of 30x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 193%. Analyst Estimate Surprise Post Earnings • Feb 25
Revenue beats expectations Revenue exceeded analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 23%, compared to a 213% growth forecast for the Pharmaceuticals industry in China. Reported Earnings • Feb 25
Full year 2020 earnings released: EPS CN¥0.60 (vs CN¥0.35 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥2.07b (up 34% from FY 2019). Net income: CN¥324.4m (up 75% from FY 2019). Profit margin: 16% (up from 12% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 51% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Feb 11
New 90-day high: CN¥46.67 The company is up 32% from its price of CN¥35.39 on 13 November 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥41.50 per share. Is New 90 Day High Low • Jan 20
New 90-day high: CN¥42.13 The company is up 20% from its price of CN¥35.17 on 23 October 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥41.50 per share. Valuation Update With 7 Day Price Move • Jan 20
Investor sentiment improved over the past week After last week's 21% share price gain to CN¥42.13, the stock is trading at a trailing P/E ratio of 76x, up from the previous P/E ratio of 63.1x. This compares to an average P/E of 32x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 228%. Is New 90 Day High Low • Oct 28
New 90-day high: CN¥39.66 The company is up 26% from its price of CN¥31.40 on 30 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥34.97 per share. Reported Earnings • Oct 28
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥288.8m, up 77% from the prior year. Total revenue was CN¥1.96b over the last 12 months, up 37% from the prior year. Valuation Update With 7 Day Price Move • Oct 13
Market bids up stock over the past week After last week's 20% share price gain to CN¥38.30, the stock is trading at a trailing P/E ratio of 79.3x, up from the previous P/E ratio of 66x. This compares to an average P/E of 40x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 158%. Is New 90 Day High Low • Oct 12
New 90-day high: CN¥38.90 The company is up 7.0% from its price of CN¥36.50 on 14 July 2020. The Chinese market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥4.95 per share. Announcement • Jul 24
Porton Pharma Solutions Ltd. to Report First Half, 2020 Results on Aug 20, 2020 Porton Pharma Solutions Ltd. announced that they will report first half, 2020 results on Aug 20, 2020 
